About IO Biotech
We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform.
Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
We aim to disrupt the way cancer is treated with our approach, solidifying our product candidates as the cornerstones for multiple solid tumors.
Leadership
We have assembled a seasoned management team with extensive experience in developing novel oncology therapies, including advancing product candidates from preclinical research through to clinical development, and ultimately to regulatory approval.

Mai-Britt Zocca, Ph.D.
Member - President and Chief Executive Officer

Amy Sullivan
Chief Financial Officer

Eva Ehrnrooth, M.D., Ph.D.
Chief Medical Officer

Muhammad Al-Hajj, Ph.D.
Chief Scientific Officer

Devin Smith
General Counsel

Diane McDowell
SVP, Clinical Development and Medical Affairs

Dan Mannix
SVP, Regulatory Affairs

Eric Faulkner
Senior Vice President, CMC

Brian Burkavage
Chief Accounting Officer
Board of Directors
Our board of directors has deep expertise in the fields of immuno-oncology, business and finance.

Peter Hirth, Ph.D.
Chairman

Kathleen Sereda Glaub, M.B.A.
Member

Christian Elling, Ph.D.
Member – Lundbeckfonden

Priyanka Belawat, Ph.D.
Member – HBM Healthcare Investments

Jack B. Nielsen, M. Sc.
Member - Vivo Capital

Vanessa Malier
Member – Kurma Partners

David V. Smith
Member

Mai-Britt Zocca, Ph.D.
Member - President and Chief Executive Officer